Bicycle Therapeutics plc (NASDAQ: BCYC) has recently secured a significant 15-year contract with the UK Nuclear Decommissioning Authority (NDA) for access to up to 400 tonnes of reprocessed uranium (RepU). This agreement positions Bicycle to leverage a sustainable supply of 212Pb, a crucial radioisotope in the development of innovative cancer therapies.
In conjunction with this contract, Bicycle has initiated a collaboration with the United Kingdom National Nuclear Laboratory (UKNNL) to extract 228Th from the RepU. This extracted isotope will be processed into 224Ra and incorporated into a bespoke 212Pb generator, developed exclusively for Bicycle by SpectronRx. These strategic partnerships are set to enhance Bicycle’s capacity to discover and develop a portfolio of Bicycle Radioconjugates (BRC) that utilize 212Pb as a therapeutic payload.
The implications of these developments are profound, as they not only underscore Bicycle’s commitment to advancing its radiopharmaceutical pipeline but also highlight the potential for significant breakthroughs in cancer treatment. With the establishment of an end-to-end supply chain for 212Pb radiopharmaceuticals, Bicycle is poised to lead in this innovative sector, potentially transforming patient outcomes in oncology. The support from the UK government and collaborations with industry leaders further solidify Bicycle’s position as a frontrunner in the field of radiopharmaceutical research and development.
Use the database as your supply chain compass →
